Dr William Schilling
Will is a research physician working at the Mahidol Oxford Tropical Medicine Research Unit (MORU), a specialty registrar in Infectious diseases and Microbiology in the UK. He is a DPhil student at the University of Oxford.
Will has been working at MORU since August 2019 and had focussed on research into community febrile illness. Since January 2020 and the appearance of COVID-19, he has turned his attention to potential therapies which may prevent infection with COVID-19, including two widely available drugs, chloroquine and hydroxychloroquine, that demonstrated promising in vitro effects against SARS-CoV-2. At the time of writing, the COVID-19 pandemic is worsening and there are no prophylactic agents nor vaccines or proven-effective treatments available. The aim is to rapidly determine if these, and other drugs, can be used as prophylactic agents against COVID-19.
Will has previous experience working in Medicine in Mbarara, Uganda.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling WHK. et al, (2021), Wellcome Open Research, 6, 71 - 71
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Chandna A. et al, (2021), Wellcome Open Research, 6, 64 - 64
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project.
Chandna A. et al, (2021), Wellcome open research, 6
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency
Schilling WHK. et al, (2020), Blood Cells, Molecules, and Diseases, 85, 102484 - 102484
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Schilling WHK. et al, (2020), Wellcome Open Research, 5, 241 - 241